2. Signaling Pathways
  3. Immunology/Inflammation
  4. STING

STING

Stimulator of Interferon Genes; TMEM173; MITA; ERIS; MPYS

STING

Related Products

PDF 0.78 MB

Stimulator of interferon genes (STING) is an integral ER-membrane protein that can be activated by 2'3'-cGAMP synthesized by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) upon binding of double-stranded DNA. It activates interferon (IFN) and inflammatory cytokine responses to defend against infection by microorganisms.

STING is a key cytosolic receptor for small nucleotides and plays a key role in anticancer and antiviral immunity. STING signaling pathway is also a critical link between innate and adaptive immunity, and induces anti-tumor immune responses. STING agonists, such as endogenous cyclic dinucleotide (CDN) cyclic GMP-AMP (cGAMP), have been used in diverse research for immunogenic tumor clearance, antiviral treatments and vaccine adjuvants.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147834
    STING agonist-9
    		Agonist
    STING agonist-9 (Compound 45) is a potent STING agonist with an EC50 of 1.2 nM and 32.82 μM against h-STING and m-STING, respectively. STING agonist-9 shows antitumor activity.
    STING agonist-9
  • HY-175166
    BMS-025
    		Agonist
    BMS-025 is a orthosteric STING agonist. BMS-025 can induces chemical shift of STING M271 residue, further activating STING IFN signaling. BMS-025 can be used for monogenic autoinflammatory disease like SAVI disease research.
    BMS-025
  • HY-170617
    hSTING agonist-1
    		Agonist
    hSTING agonist-1 (compound 17) is a potent agonist of hSTING. hSTING agonist-1 has poor oral availability. hSTING agonist-1 plays an important role in inflammation research.
    hSTING agonist-1
  • HY-156290
    SAP-04
    		Agonist
    SAP-04 is a potent and orally active STING agonist. SAP-04 exhibits potent immunomodulatory effects for cancer therapy.
    SAP-04
  • HY-172533
    3′,5′-DiOA-dC
    		Agonist
    3’,5’-DiOA-dC is a hydrophobic nucleotide lipid and a ligand for the STING agonist c-di-GMP (CDG). 3’,5’-DiOA-dC can assemble with CDG and form stable cyclic dinucleotide nanoparticles via various supramolecular forces driven by molecular recognition. 3’,5’-DiOA-dC can decrease tumor weight and volume, increase CD8 T cell, neutrophils as well as NK cell counts in tumor microenvironment in combination with CDG. 3’,5’-DiOA-dC also increases the levels of TNF-α and IFN-γ in murine melanoma model.
    3′,5′-DiOA-dC
  • HY-174170
    (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide
    		Agonist
    (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide (compound 4) is a STING agonist containing a key amide benzimidazole (ABZI) component and shows reproducible inhibition of 3H-cGAMP binding to STING with an apparent inhibition constant IC50 of 14 μM. (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide can be used for tumor research.
    (S)-2-(1-Ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(2-hydroxy-2-phenylethyl)-1H-benzo[d]imidazole-5-carboxamide
  • HY-176541
    diABZI-Mal
    		Agonist
    diABZI-Mal is a STING agonist. diABZI-Mal activates cGAS-STING pathway to induce cytokine production such as interferon-type I. diABZI-Mal promotes maturation of DC cells and efficiently induces CD8+ T immune reaction. diABZI-Mal inhibits tumor growth.
    diABZI-Mal
  • HY-168034
    diABZI-4
    		Agonist
    diABZI-4 is an oral active STING agonist with broad-spectrum antiviral activity. diABZI-4 induces the production of pro-inflammatory cytokines and lymphocyte activation by activating STING, thereby inhibiting the replication of influenza A virus (IAV), SARS-CoV-2, and human rhinovirus (HRV), with an EC50 range of 11.8-199 nM.
    diABZI-4
  • HY-173399
    hSTING activator-1
    		Agonist
    hSTING activator-1 (Compound 68) is a STING agonist. hSTING activator-1 can effectively activate multiple human STING variants (R232, H232, HAQ) with EC50 values of 56 nM, 89 nM and 51 nM, respectively. hSTING activator-1 activates the type I interferon pathway by directly binding to STING protein and stabilizing its conformation, promoting downstream IRF3 phosphorylation and cytokine release. hSTING activator-1 inhibits fibrosarcoma tumor growth and has potential in cancer research.
    hSTING activator-1
  • HY-154850
    F-CRI1
    		Agonist
    F-CRI1 is a potent STING agonist with a Kd value of 40.62 nM. F-CRI1 is a radioactive probe with 18F-labeled modification. F-CRI1 can be used to study STING visualization in the tumor microenvironment.
    F-CRI1
  • HY-152962
    STING agonist-29
    		Agonist
    STING agonist-29 (CF511) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, exhibits activity against SARS-CoV series strains.
    STING agonist-29
  • HY-172671
    STING agonist-43
    		Agonist
    STING agonist-43 (Compound 67) is a selective STING agonist (EC50: 20.53 μM). STING agonist-43 selectively amplifies cGAMP-dependent STING pathway activation by modulating STING oligomerization. B16.F10 has antitumor activity in a mouse melanoma model. STING agonist-43 can be used for the study of cancer immunity.
    STING agonist-43
  • HY-175462
    INI3069
    		Agonist
    INI3069 is a selective human stimulator of interferon gene (STING) agonist. INI3069 is promising for research of cancers.
    INI3069
  • HY-149781
    STING agonist-34
    		Agonist
    STING agonist-34 (Compound 12L) is a potent STING agonist with an IC50 value of 1.15 μM and an EC50 of 0.38 μM in THP1 cells. STING agonist-34 could be used in cancer research.
    STING agonist-34
  • HY-168887
    ZSA-51
    		Agonist
    ZSA-51 is a potent and orally active STING agonist. ZSA-51 shows anticancer activity. ZSA-51 remodeles immune microenvironment both in tumor and lymph node.
    ZSA-51
  • HY-174308
    ZSA-215
    		Agonist
    ZSA-215 is a potent and orally active STING agonist with an EC50 of 3.3 μM. ZSA-215 enhances STING signaling through promoting the phosphorylation of STING and interferon regulatory factor 3 (IRF3) and secretion of IFN-β. ZSA-215 inhibits tumor regression and long-term survival of mice in MC38 colon cancer model. ZSA-215 can be used to the study of colon cancerr.
    ZSA-215
  • HY-152958
    STING agonist-25
    		Agonist
    STING agonist-25 (CF505) is a non-nucleotide small-molecule STING agonist. STING agonist-23 activates STING, increases phosphorylation of STING, TBK1 and IRF3. STING agonist-23 promotes the levels of IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 exhibits activity against SARS-CoV series strains.
    STING agonist-25
  • HY-19943
    TLC388
    		Agonist
    TLC388 is a novel camptothecin analog with limited antitumor activity in metastatic NEC.
    TLC388
  • HY-139179
    STING agonist-14
    		Agonist
    STING agonist-14 (compound 12b) is a potent STING agonist that is efficacious across species. STING agonist-14 could activate the pathway by directly binding human STING. STING agonist-14 can be used for the research of tumours or viral infections.
    STING agonist-14
  • HY-149267
    STING agonist-30
    		Agonist
    STING agonist-30 is a potent STING agonist. STING agonist-30 exhibits STING-dependent immune activation. STING agonist-30 has extensive inhibitory effects on various viruses, including the herpes simplex virus (HSV), rotavirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    STING agonist-30
Cat. No. Product Name / Synonyms Application Reactivity